G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 1 045.65 INR -3.19% Market Closed
Market Cap: 128.1B INR
Have any thoughts about
Glenmark Life Sciences Ltd?
Write Note

Glenmark Life Sciences Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Glenmark Life Sciences Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Life Sciences Ltd
NSE:GLS
Capital Expenditures
-â‚ą1.3B
CAGR 3-Years
-24%
CAGR 5-Years
-69%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Capital Expenditures
-â‚ą27.4B
CAGR 3-Years
-30%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Capital Expenditures
-â‚ą15.5B
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Capital Expenditures
-â‚ą19.4B
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Capital Expenditures
-â‚ą4.8B
CAGR 3-Years
-19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Capital Expenditures
-â‚ą3.9B
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Glenmark Life Sciences Ltd
Glance View

Market Cap
128.1B INR
Industry
Pharmaceuticals

Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Solapur, Maharashtra. The company went IPO on 2021-08-06. The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.

GLS Intrinsic Value
715.71 INR
Overvaluation 32%
Intrinsic Value
Price
G

See Also

What is Glenmark Life Sciences Ltd's Capital Expenditures?
Capital Expenditures
-1.3B INR

Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Capital Expenditures amounts to -1.3B INR.

What is Glenmark Life Sciences Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-69%

Over the last year, the Capital Expenditures growth was 21%. The average annual Capital Expenditures growth rates for Glenmark Life Sciences Ltd have been -24% over the past three years , -69% over the past five years .

Back to Top